Is it Safe to Invest in Google With OpenAI Threats?
For the last 20 years, Google parent company Alphabet (NASDAQ:GOOG,…
Buy
71
SBRA Quote, Financials, Valuation and Earnings
Last price:
$18.20
Seasonality move
:
5.02%
Day range:
$17.25 - $17.96
52-week range:
$13.87 - $20.03
Dividend yield:
6.71%
P/E ratio:
30.32x
P/S ratio:
5.91x
P/B ratio:
1.58x
Volume:
3.2M
Avg. volume:
2.4M
1-year change:
22.45%
Market cap:
$4.3B
Revenue:
$703.2M
EPS (TTM):
$0.59
Analysts' Opinion
-
Consensus RatingSabra Health Care REIT has received a consensus rating of Hold. The company's average rating is a Hold based on 6 Buy ratings, 7 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $19.50, Sabra Health Care REIT has an estimated upside of 9% from its current price of $17.89.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $18.00 representing -0.62% downside risk from its current price of $17.89.
Fair Value
-
According to the consensus of 13 analysts, Sabra Health Care REIT has 9% upside to fair value with a price target of $19.50 per share.
SBRA vs. S&P 500
-
Over the past 5 trading days, Sabra Health Care REIT has overperformed the S&P 500 by 2.12% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Sabra Health Care REIT does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Sabra Health Care REIT has grown year-over-year revenues for 5 quarters straight. In the most recent quarter Sabra Health Care REIT reported revenues of $183.5M.
Earnings Growth
-
Sabra Health Care REIT has grown year-over-year earnings for 2 quarters straight. In the most recent quarter Sabra Health Care REIT reported earnings per share of $0.17.
Enterprise value:
6.6B
EV / Invested capital:
1.30x
Price / LTM sales:
5.91x
EV / EBIT:
25.92x
EV / Revenue:
9.21x
PEG ratio (5yr expected):
0.16x
EV / Free cash flow:
19.61x
Price / Operating cash flow:
12.58x
Enterprise value / EBITDA:
15.56x
Gross Profit (TTM):
$487M
Return On Assets:
2.64%
Net Income Margin (TTM):
19.55%
Return On Equity:
5.13%
Return On Invested Capital:
2.72%
Operating Margin:
36.72%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Income Statement | ||||||
| Revenue | $623M | $652.9M | $720M | $166.7M | $183.5M | |
| Gross Profit | $450.7M | $451.5M | $487M | $112.8M | $123.6M | |
| Operating Income | $215.7M | $229.5M | $265.9M | $58M | $67.4M | |
| EBITDA | $178.4M | $337.2M | $425.9M | $98M | $111.3M | |
| Diluted EPS | -$0.56 | $0.20 | $0.59 | $0.11 | $0.17 | |
| Period Ending | 2021-03-31 | 2022-03-31 | 2023-03-31 | 2024-03-31 | 2025-03-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $274.3M | $185M | $171.4M | $214.3M | $155.3M | |
| Total Assets | $6B | $5.9B | $5.6B | $5.4B | $5.2B | |
| Current Liabilities | $123.5M | $118.3M | $222.6M | $258.9M | $112.1M | |
| Total Liabilities | $2.5B | $2.5B | $2.6B | $2.6B | $2.5B | |
| Total Equity | $3.5B | $3.4B | $3B | $2.8B | $2.7B | |
| Total Debt | $2.3B | $2.4B | $2.4B | $2.5B | $2.4B | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $320.9M | $285.1M | $338M | $52.8M | $80.3M | |
| Cash From Investing | -$65.8M | -$23.3M | -$112.2M | -$13.2M | -$16.4M | |
| Cash From Financing | -$245.3M | -$234.5M | -$262.6M | -$20.2M | -$101.2M | |
| Free Cash Flow | $320.9M | $285.1M | $338M | $52.8M | $80.3M | |
SBRA
Sector
Market Cap
$4.3B
$994.9M
Price % of 52-Week High
89.32%
80.29%
Dividend Yield
6.71%
3.3%
Shareholder Yield
4.96%
3.72%
1-Year Price Total Return
22.45%
--
Beta (5-Year)
0.887
0.775
Dividend yield:
6.71%
Annualized payout:
$1.20
Payout ratio:
200.39%
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$17.56
200-day SMA
Buy
Level
$17.45
Bollinger Bands (100)
Buy
Level
16.62 - 17.6
Chaikin Money Flow
Buy
Level
69.9M
20-day SMA
Buy
Level
$17.56
Relative Strength Index (RSI14)
Buy
Level
56.56
ADX Line
Buy
Level
10.66
Williams %R
Neutral
Level
-33.5937
50-day SMA
Buy
Level
$17.25
MACD (12, 26)
Buy
Level
0.09
25-day Aroon Oscillator
Buy
Level
24
On Balance Volume
Neutral
Level
36.9M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (0.7465)
Buy
CA Score
(Annual)
Level (-0.1238)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (9)
Buy
Ohlson Score
Level (-0.7576)
Buy
Piotroski F Score
(Annual)
Level (7)
Buy
Quality Ratio Score
Level (2)
Buy
Fundamental Score
Level (6)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Sabra Health Care REIT Inc is a healthcare facility real estate investment trust. The company operates one segment that owns and invests in healthcare real estate. All of the company's revenue is generated in the United States. Sabra's operations consist of nursing facilities, assisted living centers, and mental health facilities.
Stock Forecast FAQ
In the current month, SBRA has received 6 Buy ratings 7 Hold ratings, and 0 Sell ratings. The SBRA average analyst price target in the past 3 months is $19.50.
-
Where Will Sabra Health Care REIT Stock Be In 1 Year?
According to analysts, the consensus estimate is that Sabra Health Care REIT share price will rise to $19.50 per share over the next 12 months.
-
What Do Analysts Say About Sabra Health Care REIT?
Analysts are divided on their view about Sabra Health Care REIT share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Sabra Health Care REIT is a Sell and believe this share price will drop from its current level to $18.00.
-
What Is Sabra Health Care REIT's Price Target?
The price target for Sabra Health Care REIT over the next 1-year time period is forecast to be $19.50 according to 13 Wall Street analysts, 6 of them rate the stock a Buy, 0 rate the stock a Sell, and 7 analysts rate the stock a Hold.
-
Is SBRA A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Sabra Health Care REIT is a Hold. 7 of 13 analysts rate the stock a Hold at this time.
-
How Can I Buy Shares Of SBRA?
You can purchase shares of Sabra Health Care REIT via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Sabra Health Care REIT shares.
-
What Is The Sabra Health Care REIT Share Price Today?
Sabra Health Care REIT was last trading at $18.20 per share. This represents the most recent stock quote for Sabra Health Care REIT. Yesterday, Sabra Health Care REIT closed at $17.89 per share.
-
How To Buy Sabra Health Care REIT Stock Online?
In order to purchase Sabra Health Care REIT stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Broadcom Stock a Millionaire Maker?
Broadcom (Nasdaq: AVGO) stock has gone up more than 64%…
Is Berkshire The Best Stock to Buy in a Bad Market?
Berkshire Hathaway (NYSE:BRK.A, BRK.B) has historically been one of the…
Stock Ideas
Buy
70
Is MSFT Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 37x
Sell
40
Is AAPL Stock a Buy?
Market Cap: $3T
P/E Ratio: 33x
Buy
60
Is NVDA Stock a Buy?
Market Cap: $2.8T
P/E Ratio: 39x
Alerts
Buy
60
RGC alert for May 7
Regencell Bioscience Holdings [RGC] is up 19.21% over the past day.
Buy
77
FARO alert for May 7
Faro Technologies [FARO] is up 0.14% over the past day.
Buy
53
SRPT alert for May 7
Sarepta Therapeutics [SRPT] is down 19.76% over the past day.
